2,249
Participants
Start Date
February 28, 2009
Primary Completion Date
August 31, 2010
Study Completion Date
August 31, 2010
1a - rMenB+OMV NZ and routine vaccines
One dose of rMenB vaccine and routine vaccine at study month 12.
1b - rMenB+OMV NZ and routine vaccines
One dose of rMenB vaccine at study month 12 and routine vaccine at study month 13.
2a - Routine and rMenB+OMV NZ vaccines
One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.
2b - rMenB+OMV NZ and routine vaccines
Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.
3a - rMenB+OMV NZ and routine vaccines
One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations
One dose of rMenB vaccine at study month 12 and one dose of routine vaccine study month 13.
4a- rMenB+OMV NZ and routine vaccines
One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
4b - rMenB+OMV NZ and routine vaccines
One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
Sommer, Vienna
Prieler, Neufeld A.d. Leitha
Häckel, Kirchdorf
Angermayr, Wels
Maurer, Salzburg
Grässl, Hall in Tirol
Altenburger, Eisenstadt
Site 47, Lahti
Dipartimento di Scienze della Salute, Genova
Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena Italia, Milan
Pediatria dell' Ospedale Sacco, Milan
Site 53, Turku
Site 50, Pori
Ospedale Maggiore di Novara, Novara
Site 92, Espelkamp
Site 81, Porta Westfalica
Site 99, Detmold
Site 52, Tampere
Site 64, Fulda
Site 45, Kotka
Site 51, Seinäjoki
Site 35, Kokkola
Site 46, Kuopio
Site 57, Marbach A. N.
Site 65, Schwieberdingen
ASL/TA, Taranto
Site 58, Lauffen am Neckar
Site 80, München
Site 83, München
Site 97, München
Site 96, München
Site 91, Műnchen
Site 94, Weilheim
Site 95, Freising
Site 49, Oulu
Site 27, Boskovice
Site 19, Brno
Site 22, Chomutov
Site 12, Havlíčkův Brod
Fakulta vojenskeho zdravotnictví, Hradec Králové
Site 28, Hranice I-mesto
Site 13, Humpolec
Site 25, Kladno
Site 21, Kolín
Site 10, Liberec
Site 24, Litoměřice
Site 17, Ostrava
Site 18, Ostrava-Poruba
Site 16, Pilsen
Site 26, Rumburk
Site 23, Ústí nad Labem
Site 30, Espoo
Site 31, Helsinki
Site 32, Helsinki
Site 34, Järvenpää
Site 33, Vantaa
Site 48, Vantaa
Istituto di Igiene e Medicina Preventiva - Università degli Studi di Sassari, Sassari
Universita degli Studi di Messina, Policlinico G. Martino, Messina
Lead Sponsor
Novartis Vaccines
INDUSTRY